This month’s issue of Going on Trial takes a sneak peek at some early null results from a small trial of a cannabidiol-based drug for autism, among other recent drug developments.

The drug clemastine and other compounds that fortify the protective sheath around neurons may prove therapeutic for some genetic neurodevelopmental conditions.

New data from clinical trials of arbaclofen and oxytocin underscore the murkiness of null results. Plus, researchers seek clarity on the neurodevelopmental effects of oxytocin during childbirth.

The retracted studies mar hope for the drug’s use in depression.

This month’s issue of the Going on Trial newsletter explores why it’s more fun to have a beer with friends than by yourself — and how that informs an ongoing clinical trial for autism.

The phase 2A trial has its detractors despite positive animal results and is being sponsored by a company that is struggling financially.

If a therapy for autism’s core traits makes it to market, it will likely take one of three forms, the researchers say.

The result raises hopes for an ongoing clinical trial in people — and offers fresh insight into the biology of imprinting and the UBE3A antisense transcript.

Some conditions are too rare for conventional drug trials, leading some scientists to test bespoke treatments in single participants. Gleeson discusses the merits — and limitations — of these tiny trials.

This month’s issue of the Going on Trial newsletter examines personalized therapies for rare conditions, Acadia’s new drug for Rett syndrome and developments in a cord-blood program, among other autism-related drug trial news.